In lupus-prone mixed New Zealand and MRL/MpJ-Fas (lpr) mice, treatment with anti-CD20 mAbs resulted in delayed disease onset, reduced T-cell activation, and slower clinical progression [83]. This evidence concerns the gene FAS and systemic lupus erythematosus.